Neuroendocrine Tumors (NETs) clinical trials
36 active trials name this condition (recorded in the registry as “Neuroendocrine Neoplasm”) . Describe your situation to see which ones you may be eligible for.
Refine by biomarker
By location
- Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors
- Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
- SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
- Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
- Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
- Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)
- Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
- The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)
- Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
- A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
- Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
- A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
- A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
- Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
- Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
- A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
- Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
- Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
- Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
- Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake
- Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors
- F-Tryptophan PET/CT in Human Cancers
- Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
- Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
- Project: Every Child for Younger Patients With Cancer
- Integrated Cancer Repository for Cancer Research
- Resilience and Equity in Aging, Cancer, and Health (REACH)
- 211At-MABG in Adults With Advanced Neuroendocrine Cancers
- A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG
- Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies
- Ultralow Dose PET Imaging of 18F-FDOPA
- Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.
- Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
- Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Neuroendocrine Neoplasm” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.